hs-CRP and Inflammation Markers: The Blood Tests That Hint at Heart Risk

A reader wrote to us last month with a photo of her lab report, one line circled in red pen: hs-CRP 3.4. Her cholesterol was fine. Her blood pressure was fine. She wanted to know whether this one number meant her heart was quietly on fire.

She is not alone in asking. Searches for hs-CRP and inflammation markers have climbed sharply, and the timing is not random. In August 2024, a long-running study of nearly 28,000 women reported that a single hs-CRP measurement taken in middle age still predicted heart attacks and strokes 30 years later, independently of cholesterol. That followed a 2023 US approval of an anti-inflammatory medicine specifically for lowering cardiovascular risk, the first of its kind, and a wave of social media posts promising to “test your inflammation” at home.

As of early 2025, the science is genuinely interesting and genuinely incomplete. This piece sorts the two apart.

What is hs-CRP, and how is it different from a regular CRP test?

C-reactive protein is a molecule the liver releases into the bloodstream whenever the body senses injury or infection. Think of it as smoke from a fire: it does not tell you what is burning, only that something is. A standard CRP test is designed to catch big fires. It is the test a hospital runs when someone has pneumonia or a flare of rheumatoid arthritis, and results are often in the tens or hundreds of milligrams per liter.

The high-sensitivity version, hs-CRP, uses the same protein but a far more precise assay, one that can reliably detect levels below 1 mg/L. That matters because the inflammation involved in heart disease is not a blaze. It is a slow smolder inside artery walls, and it produces only a faint trace of CRP. A regular CRP test would simply report “normal” for almost everyone with cardiovascular risk; the high-sensitivity test can separate a reading of 0.5 from a reading of 2.8, and that gap carries prognostic information.

Both tests measure exactly the same substance, so a laboratory may list the result under either name. The clinically meaningful difference is the range in which the test is accurate and the question it is being asked to answer. A standard CRP asks, “Is this person acutely ill?” An hs-CRP asks, “Over the coming years, is this person’s cardiovascular risk higher or lower than their cholesterol alone suggests?”

The test itself is ordinary: a single tube of blood drawn from a vein, usually without any need to fast, with results back within days. What makes it worth understanding is not the needle but the interpretation, which is where most confusion starts.

What changed recently: why hs-CRP is trending again

The inflammation story in cardiology has moved in distinct steps, and three of them are driving current interest.

The first came in August 2017, when the CANTOS trial, published in the New England Journal of Medicine and indexed on PubMed, tested canakinumab, an injectable antibody that blocks an inflammatory signal called interleukin-1 beta. In more than 10,000 people who had already had a heart attack and had an hs-CRP of 2 mg/L or higher, the medicine lowered the rate of further cardiovascular events by about 15 percent without changing cholesterol at all. That was the first randomized proof that reducing inflammation alone could protect arteries. The medicine was never approved for heart disease, partly because of a small increase in fatal infections, but the principle held.

The second step was colchicine, an old gout medicine. Two randomized trials, COLCOT in November 2019 and LoDoCo2 in August 2020, found that it reduced major cardiovascular events in people with established coronary disease by roughly a quarter to a third. In June 2023 the US Food and Drug Administration approved a colchicine product to reduce cardiovascular risk in adults with atherosclerotic disease or multiple risk factors, the first anti-inflammatory approval for that purpose. A later trial of colchicine started immediately after a heart attack, reported in November 2024, did not show benefit, which is a reminder that timing and patient selection matter.

The third step, and the one most relevant to someone staring at a lab slip, is the August 2024 report from the Women’s Health Study. In 27,939 initially healthy women followed for 30 years, those in the top fifth for hs-CRP had about a 70 percent higher risk of a major cardiovascular event than those in the bottom fifth. Combined with LDL cholesterol and lipoprotein(a), a single blood draw stratified risk three decades out.

What does an hs-CRP result actually mean?

The categories most laboratories print come from a 2003 joint statement by the American Heart Association and the Centers for Disease Control and Prevention, and they have held up remarkably well. The table below shows the ranges and how clinicians typically read them.

hs-CRP (mg/L)	Relative cardiovascular risk	How clinicians usually interpret it
Below 1.0	Lower	Low-grade vascular inflammation unlikely to be adding risk
1.0 to 3.0	Average	Typical for middle-aged adults; interpreted alongside other risk factors
Above 3.0	Higher	May tilt a borderline decision toward more intensive prevention
Above 10.0	Not interpretable for heart risk	Suggests acute infection, injury or another illness; repeat in 2–3 weeks once well

Two features of this table deserve emphasis. The first is that the categories describe relative risk, not absolute risk. A reading of 3.5 in a 35-year-old non-smoker with normal cholesterol and blood pressure still translates to a low chance of a heart attack in the next decade. The same reading in a 62-year-old with diabetes carries more weight because it is multiplying a larger baseline.

The second is that a single value is a snapshot. CRP can roughly double after a hard workout, a dental infection or a bad cold, and Mayo Clinic and MedlinePlus both advise that an unexpectedly high result should be repeated about two weeks later, with the lower of the two values used. People sometimes see one elevated number and assume a chronic problem when the real cause was a sinus infection the week before the draw.

The categories were derived mostly from adults in their 40s to 70s, so they are not validated for children, and they are not designed to diagnose arthritis, bowel disease or any specific condition.

How inflammation damages arteries in the first place

Atherosclerosis, the buildup of fatty deposits called plaque inside artery walls, used to be described as a plumbing problem: cholesterol clogs the pipe. The modern picture is closer to a wound that never heals.

It starts when particles carrying LDL cholesterol slip beneath the inner lining of an artery, usually where blood flow is turbulent, such as a branch point. Once trapped, the particles become chemically modified, and the lining responds as it would to any intruder. It sends out signals called cytokines, small proteins that recruit immune cells. White blood cells called monocytes crawl into the wall, swallow the modified cholesterol, and swell into “foam cells.” A plaque is, in large part, a graveyard of these cells and the debris they leave behind.

Here is the link to the blood test. One of those cytokines, interleukin-6, travels to the liver and instructs it to make C-reactive protein. So hs-CRP in the blood is a downstream echo of interleukin-6 activity in tissues, including, but not only, the arteries. It is a marker of the process, not the process itself. Experiments that genetically lower CRP do not reduce heart disease, which is why researchers describe CRP as a bystander that reports on the fire rather than fuel that feeds it.

Inflammation also decides how a plaque behaves. Immune cells release enzymes that thin the fibrous cap covering the plaque. A thin, inflamed cap is more likely to rupture, and rupture is what triggers the sudden clot behind most heart attacks and many strokes. This explains a pattern that puzzled cardiologists for decades: roughly half of heart attacks occur in people with cholesterol levels considered acceptable. Cholesterol builds the plaque; inflammation often pulls the trigger.

What the evidence actually says about hs-CRP and heart risk

Evidence in medicine comes in grades, and hs-CRP sits at different grades depending on the question asked.

As a predictor of future events: strong observational evidence. Dozens of cohort studies, together following well over 100,000 people, show that higher hs-CRP tracks with higher rates of heart attack, stroke and cardiovascular death, even after adjusting for cholesterol, blood pressure, smoking and diabetes. A pooled analysis of 54 studies found risk rose by about a third for each tripling of hs-CRP. The 30-year women’s data from 2024 extends that into the very long term. This is consistent, large-scale, and about as solid as observational data gets.

As a cause of heart disease: the evidence is against it. Mendelian randomization studies, which use inherited gene variants as a natural experiment, find that people born with lifelong lower CRP are not protected from heart attacks. CRP is a signal, not a culprit.

As a test that improves decisions: moderate evidence. Adding hs-CRP to standard risk calculators shifts a modest proportion of people, often around 5 to 10 percent, from one risk category to another. The 2008 JUPITER randomized trial showed that people with normal LDL but hs-CRP above 2 mg/L benefited from a statin, which is the main reason the test entered guidelines. What has never been done is a trial randomizing people to be tested versus not tested and following outcomes. The AHA and American College of Cardiology therefore list hs-CRP as a “risk-enhancing factor” rather than a routine screen, and the US Preventive Services Task Force found insufficient evidence to recommend it for everyone.

As a treatment target: randomized evidence exists, with limits. CANTOS, COLCOT and LoDoCo2 show that lowering inflammation reduces events in people with established disease. Whether treating a high hs-CRP in an otherwise healthy person helps is still an open question.

Who should consider an hs-CRP test, according to guidelines?

The honest answer is: fewer people than the internet suggests, and more than currently get one.

The 2018 and 2019 American College of Cardiology and American Heart Association prevention guidelines place hs-CRP in a specific role. After a clinician estimates ten-year risk using age, sex, cholesterol, blood pressure, smoking and diabetes, some people land in a gray zone, roughly a 5 to 20 percent chance of a cardiovascular event over the next decade. For them, the decision to start preventive medicine is genuinely close, and extra information can tip it. An hs-CRP of 2 mg/L or higher is one of several risk-enhancing factors, alongside family history of early heart disease, chronic kidney disease, inflammatory conditions such as psoriasis or lupus, a history of preeclampsia or early menopause, and elevated lipoprotein(a).

In that setting the test earns its place. A borderline-risk 55-year-old with an hs-CRP of 4 mg/L has a different conversation ahead than one with a reading of 0.6.

Where the test adds little is at the extremes. Someone at very low risk, say a 30-year-old with excellent numbers, will not have their plan changed by any hs-CRP value, and someone who has already had a heart attack is already a candidate for the most intensive prevention regardless of the result. Cleveland Clinic and Mayo Clinic both make this point in their patient guidance: hs-CRP is not a general screening test for healthy adults.

Guidelines also caution against ordering it during or shortly after an infection, injury, surgery or flare of an inflammatory disease, because the result will reflect that event rather than vascular risk. Pregnancy, hormone therapy and some medicines also alter baseline values, which is why the order should come from someone who knows your history.

Which other inflammation markers do doctors use, and how do they compare?

hs-CRP is the best-studied inflammation marker for the heart, but it is not the only one you may see on a report.

The erythrocyte sedimentation rate, or ESR, measures how quickly red blood cells settle in a tube over an hour; inflammatory proteins make them clump and fall faster. It is cheap and old, rises and falls more slowly than CRP, and is affected by anemia, age and sex. ESR is useful for tracking arthritis or certain infections but has almost no role in estimating heart risk.

Interleukin-6 is the cytokine that tells the liver to make CRP, and it sits closer to the actual biology. Several studies suggest it predicts events at least as well as hs-CRP, and new medicines in development, including an antibody called ziltivekimab currently in late-stage trials, target it directly. For now it remains largely a research test.

Fibrinogen is a clotting protein that also rises with inflammation. It predicts risk in population studies but is not routinely measured because it adds little once hs-CRP is known.

Lipoprotein-associated phospholipase A2, or Lp-PLA2, is an enzyme carried on LDL particles that was once marketed as a “vascular-specific” inflammation test. Medicines that blocked it failed to reduce heart attacks in large trials, and interest has faded.

The white blood cell count, part of a routine blood panel, correlates loosely with inflammation and risk but is far too nonspecific to guide prevention.

A practical rule: if a report lists several inflammation markers, hs-CRP is the one with guideline backing for heart risk. The others answer different questions, and a cluster of mildly abnormal values is more often noise than a hidden diagnosis.

What raises hs-CRP that has nothing to do with your heart?

Because CRP responds to any inflammation anywhere, a long list of ordinary situations can push the number up and make an artery look guiltier than it is.

Acute illness is the obvious one. A cold, a urinary infection, a tooth abscess or a bout of gastroenteritis can lift CRP into the tens for a week or two. Injury and surgery do the same; a sprained ankle is enough. Mayo Clinic notes that even a hard training session can raise it transiently, which is why some clinicians suggest avoiding vigorous exercise the day before a draw.

Chronic conditions add a steadier background signal. Excess body fat, particularly fat around the organs, releases interleukin-6 continuously, and hs-CRP rises in step with waist circumference. Sleep apnea, periodontal disease, chronic bronchitis and inflammatory bowel disease all raise baseline levels. Autoimmune conditions such as rheumatoid arthritis, lupus and psoriasis can push values well above the cardiovascular range; in those settings the test is being used to monitor the disease, not the arteries.

Smoking raises hs-CRP, and quitting lowers it over months. Oral estrogen, whether as contraception or menopausal hormone therapy, increases CRP production in the liver without necessarily increasing vascular inflammation, a quirk that complicates interpretation in women taking it. Pregnancy does the same. Depression and chronic psychological stress are associated with modestly higher values in population studies.

There is also a genetic component: inherited variants account for perhaps a quarter to a half of the differences in baseline CRP between healthy people, and some people simply run higher or lower for life.

None of this makes the test useless. It makes context essential, and it explains why a thoughtful clinician asks “What else was going on?” before reacting to a single value.

Can you lower hs-CRP, and does lowering it matter?

These are two different questions, and conflating them is the source of many confident but misleading claims.

Lowering the number is achievable. The lifestyle changes that reduce hs-CRP are, reassuringly, the same ones that reduce heart risk by every other measure. Weight loss produces the most reliable drop: in trials, losing around 5 to 10 percent of body weight typically lowers hs-CRP by a quarter to a third. Regular aerobic exercise lowers it independently of weight, with the effect building over months rather than days. Quitting smoking brings values down substantially within a year. Dietary patterns rich in vegetables, legumes, whole grains, nuts, fish and olive oil, the Mediterranean pattern tested in randomized trials, lower hs-CRP modestly, while diets heavy in refined carbohydrates and processed meat raise it. Treating sleep apnea and periodontal disease lowers it. Adequate sleep helps; chronic short sleep is associated with higher values.

Whether the drop in the number is itself what protects you is less clear. Because CRP is a marker rather than a cause, the reasonable interpretation is that the behaviors are working on the underlying biology and the test is reporting the improvement. There is no randomized trial showing that chasing a specific hs-CRP target through lifestyle alone prevents heart attacks, and expert guidance does not set one.

Supplements deserve a plain statement. Omega-3 fatty acids, curcumin, vitamin D and various “anti-inflammatory” blends have been tested in small trials with inconsistent, usually small effects on hs-CRP and no demonstrated effect on heart events through that pathway. The NIH Office of Dietary Supplements summaries make clear that none should be taken on the strength of an hs-CRP result without discussing it with a clinician, particularly for anyone on blood thinners.

Medicines that act on inflammation: what the trials showed

Three classes of medicine have randomized evidence relevant to hs-CRP, and each tells a slightly different story. None of the following is advice to start, stop or change anything; those decisions sit with the prescribing clinician.

Statins lower hs-CRP by roughly 15 to 40 percent in addition to lowering LDL cholesterol, and the JUPITER trial of 2008 showed that in people with normal LDL but hs-CRP of 2 mg/L or higher, a statin cut heart attacks, strokes and cardiovascular deaths by nearly half over about two years. Later analyses found that people who reached both a low LDL and a low hs-CRP did best, which is the origin of the idea of a “dual target.” Whether the hs-CRP reduction contributes to the benefit or simply reflects it remains debated.

Colchicine, which dampens the activity of inflammatory white blood cells, reduced recurrent cardiovascular events in COLCOT and LoDoCo2, trials enrolling people with existing coronary disease. Its 2023 US approval was for adults with established atherosclerotic disease or multiple risk factors. A 2024 trial that began it within days of a heart attack found no benefit, so its place is being refined. Gastrointestinal side effects are the most common reason people stop it.

Canakinumab, the antibody studied in CANTOS, proved the inflammation hypothesis but was not approved for heart disease because the benefit was modest and infections slightly increased. Methotrexate, an older anti-inflammatory, did not lower hs-CRP in people without high baseline inflammation and did not reduce events, an instructive failure: suppressing inflammation only helps when inflammation is actually present.

The takeaway for a reader with a high hs-CRP is that these are tools for people with defined cardiovascular disease, chosen on the basis of the whole picture, not a single lab value.

hs-CRP versus cholesterol, Lp(a) and coronary calcium: how the pieces fit

Risk assessment is not a contest between tests; each one answers a different question, and the most useful picture comes from stacking them.

LDL cholesterol measures how much plaque-building material is circulating. It is causal, modifiable and the backbone of prevention. Lipoprotein(a), or Lp(a), is a genetically determined cholesterol particle that is especially prone to lodging in artery walls; roughly one in five people inherits a high level, and it is usually measured once because it barely changes. Coronary artery calcium scoring is a low-dose CT scan that counts calcified plaque already present in the heart’s arteries; it measures the disease that has accumulated rather than the risk of future accumulation.

hs-CRP occupies a different corner. It does not measure cholesterol or plaque; it measures how biologically active the process is right now. A person with a calcium score of zero and an hs-CRP of 4 mg/L has no visible disease but a hot environment; a person with a calcium score of 300 and an hs-CRP of 0.5 has established disease that appears quiet. Those are different clinical situations, and each shapes the conversation about how aggressively to act.

The 2024 women’s study made this stacking concrete: participants high in all three of LDL, Lp(a) and hs-CRP had about two and a half times the 30-year cardiovascular risk of those low in all three. Each marker contributed independently.

Guidelines reflect this layering. Calcium scoring is the preferred tiebreaker when risk is uncertain, because it has the strongest evidence for changing decisions; hs-CRP and Lp(a) are risk enhancers that refine the estimate. A clinician choosing between them will consider age, family history, radiation exposure and what would actually change the plan.

Common myths about hs-CRP and "inflammation"

Myth: a high hs-CRP means you have heart disease. It does not diagnose anything. It raises the probability of future events in a population; it says nothing certain about an individual’s arteries, and a recent cold could explain the whole number.

Myth: a low hs-CRP means you are safe. Plenty of heart attacks occur in people with hs-CRP under 1 mg/L. Cholesterol, blood pressure, smoking, diabetes and family history remain the heavy hitters, and a reassuring inflammation marker does not cancel them.

Myth: “inflammation” is the root cause, and cholesterol does not matter. This claim circulates widely online. Genetic studies and dozens of randomized trials show LDL cholesterol is causal. Inflammation and cholesterol are partners in the same process, not rivals.

Myth: you can diagnose chronic inflammation from a home test kit. Finger-prick hs-CRP kits exist, but a single value without clinical context, without a repeat, and without a clinician to weigh it is more likely to generate anxiety than insight.

Myth: an anti-inflammatory diet or supplement will “reset” your CRP in days. Lifestyle changes lower hs-CRP over weeks to months, modestly, and no supplement has been shown to reduce heart events through this pathway.

Myth: taking an anti-inflammatory painkiller before the test will lower your reading. Common over-the-counter pain relievers do not meaningfully reduce CRP, and some of them are associated with higher cardiovascular risk when used regularly.

Myth: hs-CRP is only for people over 50. The 2024 data show that values measured in women in their 40s and 50s predicted events three decades later, and the underlying biology starts far earlier. The counterweight is that the test rarely changes management in young adults, which is why guidelines do not recommend routine testing at any age.

How to prepare for the test and read a repeat result

Preparation is simple, and most of it is about timing rather than what you eat.

Fasting is not required for hs-CRP alone, though laboratories often draw it with a lipid panel that may call for fasting; follow whatever instructions come with the order. Schedule the draw when you have been well for at least two weeks: no fever, no infection, no new injury, no recent dental work or vaccination, no surgery in the past month. Mayo Clinic suggests avoiding strenuous exercise the day before. Tell the clinician about any flare of an inflammatory condition, any oral estrogen, and whether you are pregnant.

If the first result is above 3 mg/L, the standard advice is to repeat it in about two weeks and use the lower of the two values, because the lower one is more likely to reflect your true baseline. If a result is above 10 mg/L, it is not interpreted for heart risk at all; it points to a current illness, and the sensible step is to find and address the cause, then retest once recovered.

Reading a repeat after lifestyle changes requires patience and a tolerance for noise. Day-to-day biological variation in hs-CRP is substantial, around 30 to 40 percent in some studies, so a shift from 2.8 to 2.3 may mean nothing. Trends over several months, with values that cluster consistently lower, are more convincing than any single comparison. Many clinicians do not recheck hs-CRP at all once a prevention plan is in place, because the plan is driven by overall risk rather than by that one marker.

Keep copies of your results. A value from five years ago, drawn when you were well, is a useful anchor for interpreting today’s number.

When to see a doctor

An hs-CRP result is never an emergency in itself, but the symptoms that sometimes prompt people to search for it can be. Call emergency services immediately for chest pressure, tightness or pain lasting more than a few minutes, especially if it spreads to the arm, jaw, neck or back; for sudden shortness of breath; for sudden weakness or numbness on one side of the body, facial drooping, slurred speech or confusion; or for fainting. These are signs of a possible heart attack or stroke, and no blood test should delay the call.

Arrange a prompt, non-emergency appointment if a reading comes back above 10 mg/L and you do not have an obvious explanation such as a recent infection, if it stays high on a repeat test, or if a raised value comes with unexplained fever, night sweats, weight loss, persistent joint pain and swelling, a new rash, or a change in bowel habit. Those combinations point toward an inflammatory or infectious condition that deserves evaluation on its own terms.

Book a routine conversation if your hs-CRP is between 1 and 10 mg/L and you have never had a formal cardiovascular risk assessment, or if your last one placed you in a borderline category. That is precisely the situation in which the test is designed to inform a decision, and the decision should be made with someone who can see your cholesterol, blood pressure, glucose, family history and medicines together.

Do not start, stop or adjust any prescribed medicine on the basis of an hs-CRP result, and do not begin a supplement without checking first; several interact with blood thinners and blood pressure medicines. If you are already on a statin or an anti-inflammatory for your heart and are considering changes, the prescribing clinician is the right person to weigh the result, because they can interpret it against the reason the medicine was started.

What a single hs-CRP can and cannot tell you about the decades ahead

Return to the reader with 3.4 circled in red pen. What should she make of it?

On the population level, her number places her in the higher-risk third, and the 2024 Women’s Health Study would say that, all else equal, women in her position had roughly 70 percent more cardiovascular events over 30 years than women with the lowest values. That sounds alarming until it is translated into absolute terms. If her baseline ten-year risk, calculated from age, cholesterol and blood pressure, is 3 percent, a risk-enhancing factor might nudge it toward 4 or 5 percent. Real, worth knowing, but not a verdict.

What the number cannot do is tell her why it is high. It could be visceral fat, a smoldering gum infection, an oral contraceptive, a cold she forgot about, an inherited tendency, or genuinely active vascular inflammation. Each has a different response, and only the last is directly about her heart. The first useful step is a repeat test when she is well. The second is a full risk assessment, if she has not had one.

The larger lesson is about what blood tests are for. hs-CRP is one of the better examples of a marker that improved understanding of disease, changed how trials were designed, and earned a defined place in guidelines without becoming a test everyone needs. Its value lies in the gray zone, in the borderline patient whose next step is genuinely uncertain. For that person it is a quiet, useful voice. For everyone else it is context, and context is read best by a clinician who knows the whole story rather than by a reader with a red pen.

Frequently asked questions

What is a normal hs-CRP level for heart health?

For cardiovascular risk, values below 1 mg/L are considered lower risk, 1 to 3 mg/L average, and above 3 mg/L higher risk. These categories come from a joint American Heart Association and CDC statement and describe relative risk across populations, not a diagnosis. Anything above 10 mg/L is not interpreted for heart risk because it usually signals a current infection or injury.

What is the difference between CRP and hs-CRP?

They measure the identical protein, C-reactive protein, but with different assays. A standard CRP test detects the large rises seen in infections or arthritis flares. The high-sensitivity test can reliably measure levels below 1 mg/L, the faint signal associated with slow inflammation in artery walls. The high-sensitivity version is the one used for cardiovascular risk assessment.

Which inflammation markers are linked to heart disease?

hs-CRP is the inflammation marker with guideline support for estimating heart risk. Interleukin-6 predicts events at least as well but remains mostly a research test. Fibrinogen and white blood cell count correlate loosely with risk but add little once hs-CRP is known. The erythrocyte sedimentation rate and Lp-PLA2 are not used for cardiovascular prediction in current practice.

Can hs-CRP be high without heart disease?

Yes, often. Recent infections, injuries, dental problems, hard exercise, excess body fat, sleep apnea, smoking, oral estrogen, pregnancy and autoimmune conditions all raise it. Some people inherit a higher baseline for life. That is why clinicians repeat an unexpectedly high result after two weeks of good health and interpret it alongside cholesterol, blood pressure and history rather than in isolation.

Does a high hs-CRP mean I need a statin?

Not by itself. The JUPITER trial showed that people with normal LDL but hs-CRP of 2 mg/L or higher benefited from a statin, which is why hs-CRP is a risk-enhancing factor in US guidelines. The decision depends on overall ten-year risk, other enhancers and personal preferences, and belongs to the clinician who can see the full picture.

How quickly does hs-CRP change with lifestyle changes?

Over weeks to months rather than days. Weight loss of 5 to 10 percent typically lowers hs-CRP by a quarter to a third, regular aerobic exercise and smoking cessation bring further reductions within months, and Mediterranean-style eating produces modest drops. Because day-to-day variation is large, a consistent downward trend across several tests means more than any single comparison.

Should I fast before an hs-CRP blood test?

Fasting is not required for hs-CRP itself, although it is often drawn together with a lipid panel that may require it, so follow the specific instructions you are given. More important is timing: wait until you have been free of infection, injury, dental work or surgery for about two weeks, and avoid strenuous exercise the day before, since all of these can raise the result.

Is hs-CRP useful for women specifically?

The largest long-term data come from women. The Women’s Health Study, reported in August 2024, followed nearly 28,000 initially healthy women for 30 years and found that a single midlife hs-CRP measurement predicted heart attacks and strokes independently of cholesterol. One caveat is that oral estrogen raises CRP production in the liver, which can complicate interpretation for women taking it.

What do inflammation markers show after a heart attack?

They rise sharply, often into the tens or higher, because heart muscle injury is itself a strong inflammatory trigger. Values measured in the first days after a heart attack reflect that acute event and are not used to assess long-term risk. Trials of anti-inflammatory medicines started in that early window have shown mixed results, which is one reason timing matters in this field.

Can I test my hs-CRP at home with a finger-prick kit?

Kits exist, but a single value without context has limited meaning. A home result cannot tell you whether the number reflects your arteries, a passing infection or a hormone effect, and it cannot be weighed against your cholesterol, blood pressure and history. If you are curious about your heart risk, a clinician-ordered test within a full assessment is far more informative.

References

• MedlinePlus: C-Reactive Protein (CRP) Test
• Cleveland Clinic: C-Reactive Protein (CRP) Test

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.